Schrödinger, Inc.
NASDAQ:SDGRMedical - Healthcare Information Services
+$0.00 today
- Market cap
- $1.79B
- Beta
- 1.64
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$1.40
Volume 1.18M
Average 1.35M
SDGR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Schrödinger, Inc.NASDAQ: SDGR
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development declines year over year
Q3 FY2026 research & development of $34.09M fell 20.3% year over year, behind the -11.5% change in trailing-twelve-month research & development. Sequentially, it fell 16.8% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.
Context
- Research & development amounted to 67.7% of revenue in FY2025, down 29.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -20.3% toward the trailing-twelve-month pace of -11.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 173.14M USD
- Year-over-year change
- -14.2%
- 4-year CAGR
- +17.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 173.14M | -14.2% |
| FY2024 | 2024-12-31 | 201.79M | +11.0% |
| FY2023 | 2023-12-31 | 181.77M | +43.8% |
| FY2022 | 2022-12-31 | 126.37M | +39.0% |
| FY2021 | 2021-12-31 | 90.9M | — |
Research & Development vs competitors
How SDGR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.5% is the 8th highest of 9, against a peer median of +7.2%.
- Research & development amounts to 59.6% of revenue for SDGR, versus a peer median of 24.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $821.92M USD | +12.5% | +13.8% | 23.8% | |
| LTM Jun 2026 | $270.72M USD | -4.1% | +2.0% | 2615.7% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $224.7M USD | +28.2% | — | 704.5% |
| LTM Sep 2026 | $186.28M USD | +1.9% | +20.1% | 274.5% | |
| LTM Sep 2026 | $160.31M USD | -11.5% | +11.1% | 59.6% | |
| LTM Mar 2026 | $42.8M USD | +20.1% | +13.3% | 10.2% | |
| LTM Mar 2026 | $9.98M USD | -34.1% | +10.2% | — | |
| LTM Feb 2026 | $9.34M USD | +29.5% | +29.0% | 11.6% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$4.56M CAD | +1.7% | -13.6% | 24.8% |
| Peer median (excluding SDGR) | — | +7.2% | +13.3% | 24.8% | |
Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 137.93M | 180.96M | 216.67M | 207.54M | 255.87M |
| Cost of Revenue | 72.31M | 79.93M | 75.97M | 75.46M | 113.26M |
| Gross Profit | 65.62M | 101.02M | 140.69M | 132.08M | 142.61M |
| Gross Margin | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| Research & Development | 90.9M | 126.37M | 181.77M | 201.79M | 173.14M |
| Selling, General & Admin | 86.16M | 121.47M | 136.37M | 139.59M | 136.37M |
| Operating Expenses | 177.06M | 247.84M | 318.14M | 341.38M | 309.51M |
| Depreciation & Amortization | 2.85M | 4.34M | 5.55M | 6.16M | 6.02M |
| EBITDA | (97.96M) | (144.78M) | 48.47M | (179.55M) | (96.3M) |
| EBITDA Margin | -71.0% | -80.0% | 22.4% | -86.5% | -37.6% |
| Operating Income | (111.44M) | (146.82M) | (177.45M) | (209.3M) | (166.9M) |
| Operating Margin | -80.8% | -81.1% | -81.9% | -100.8% | -65.2% |
| Interest Income | 1.06M | 3.95M | 0 | 0 | 0 |
| Interest Expense | 0 | 3K | 0 | 0 | 0 |
| Other Income / Expenses | 10.64M | (2.31M) | 220.37M | 23.59M | 64.57M |
| Income Before Tax | (100.81M) | (149.12M) | 42.92M | (185.71M) | (102.33M) |
| Pre-Tax Margin | -73.1% | -82.4% | 19.8% | -89.5% | -40.0% |
| Income Tax Expense | 411K | 63K | 2.2M | 1.41M | 939K |
| Net Income | (100.39M) | (149.19M) | 40.72M | (187.12M) | (103.27M) |
| Net Margin | -72.8% | -82.4% | 18.8% | -90.2% | -40.4% |
| EPS (Basic) | (1.43) | (2.10) | 0.57 | (2.57) | (1.41) |
| EPS (Diluted) | (1.43) | (2.10) | 0.54 | (2.57) | (1.41) |
| Weighted Avg Shares | 70.59M | 71.17M | 71.78M | 72.67M | 73.44M |
| Weighted Avg Shares (Diluted) | 70.59M | 71.17M | 74.99M | 72.67M | 73.44M |
Schrödinger, Inc.
NASDAQ:SDGR
Intrinsic Alpha fair value
Locked
Current Price
$27.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.